{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T15:46:59Z","timestamp":1792597619913,"version":"4.5.0"},"reference-count":10,"publisher":"American Medical Association (AMA)","issue":"10","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Dermatol"],"published-print":{"date-parts":[[2026,10,1]]},"abstract":"<jats:p>This Viewpoint describes growing concerns about antifungal resistance in the treatment of patients with seborrheic dermatitis.<\/jats:p>","DOI":"10.1001\/jamadermatol.2026.2869","type":"journal-article","created":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T15:30:30Z","timestamp":1787153430000},"page":"975","source":"Crossref","is-referenced-by-count":0,"title":["Rethinking Antifungal Therapy in Seborrheic Dermatitis"],"prefix":"10.1001","volume":"162","author":[{"given":"John S.","family":"Barbieri","sequence":"first","affiliation":[{"name":"Department of Dermatology, Brigham and Women\u2019s Hospital, Boston, Massachusetts"},{"name":"Associate Editor, JAMA Dermatology"},{"name":"Evidence-Based Practice Editor, JAMA Dermatology"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ronald","family":"Berna","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, Pennsylvania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Avrom S.","family":"Caplan","sequence":"additional","affiliation":[{"name":"The Ronald O. Perelman Department of Dermatology, NYU Grossman School of Medicine, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"issue":"8","key":"dvp260004r1","doi-asserted-by":"publisher","first-page":"846","DOI":"10.1001\/jamadermatol.2024.1987","article-title":"The global prevalence of seborrheic dermatitis: a systematic review and meta-analysis.","volume":"160","author":"Polaskey","year":"2024","journal-title":"JAMA Dermatol"},{"issue":"1","key":"dvp260004r2","doi-asserted-by":"publisher","first-page":"1","DOI":"10.15585\/mmwr.mm7301a1","article-title":"Topical antifungal prescribing for Medicare Part D beneficiaries \u2014 United States, 2021.","volume":"73","author":"Benedict","year":"2024","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"4","key":"dvp260004r3","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1007\/s00403-024-02830-7","article-title":"More yeast, more problems?: reevaluating the role of Malassezia in seborrheic dermatitis.","volume":"316","author":"Chang","year":"2024","journal-title":"Arch Dermatol Res"},{"issue":"7","key":"dvp260004r4","doi-asserted-by":"publisher","first-page":"701","DOI":"10.1001\/jamadermatol.2024.1126","article-title":"Clinical course, antifungal susceptibility, and genomic sequencing of Trichophyton indotineae.","volume":"160","author":"Caplan","year":"2024","journal-title":"JAMA Dermatol"},{"issue":"1","key":"dvp260004r5","doi-asserted-by":"publisher","DOI":"10.1128\/Spectrum.00321-21","article-title":"Multifactorial mechanisms of tolerance to ketoconazole in Candida albicans.","volume":"9","author":"Xu","year":"2021","journal-title":"Microbiol Spectr"},{"issue":"9","key":"dvp260004r6","doi-asserted-by":"publisher","first-page":"2443","DOI":"10.1093\/jac\/dkx168","article-title":"Isolation of azole-resistant Aspergillus fumigatus from the environment in the south-eastern USA.","volume":"72","author":"Hurst","year":"2017","journal-title":"J Antimicrob Chemother"},{"issue":"5","key":"dvp260004r7","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD009446.pub2","article-title":"Topical anti-inflammatory agents for seborrhoeic dermatitis of the face or scalp.","volume":"2014","author":"Kastarinen","year":"2014","journal-title":"Cochrane Database Syst Rev"},{"issue":"5","key":"dvp260004r8","doi-asserted-by":"publisher","first-page":"986","DOI":"10.1016\/j.jaad.2023.12.065","article-title":"Roflumilast foam 0.3% for adolescent and adult patients with seborrheic dermatitis: a randomized, double-blinded, vehicle-controlled, phase 3 trial.","volume":"90","author":"Blauvelt","year":"2024","journal-title":"J Am Acad Dermatol"},{"issue":"6","key":"dvp260004r10","doi-asserted-by":"publisher","first-page":"434","DOI":"10.1159\/000066452","article-title":"A multicenter randomized trial of ketoconazole 2% and zinc pyrithione 1% shampoos in severe dandruff and seborrheic dermatitis.","volume":"15","author":"Pi\u00e9rard-Franchimont","year":"2002","journal-title":"Skin Pharmacol Appl Skin Physiol"},{"key":"dvp260004r9","unstructured":"Mark Cuban CostPlus Drug Company website. Accessed June 1, 2026. https:\/\/www.costplusdrugs.com\/"}],"container-title":["JAMA Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamadermatology\/articlepdf\/2853051\/jamadermatology_barbieri_2026_vp_260004_1792511060.47692.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T15:00:47Z","timestamp":1792594847000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamadermatology\/fullarticle\/2853051"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,1]]},"references-count":10,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2026,10,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamadermatol.2026.2869","relation":{},"ISSN":["2168-6068"],"issn-type":[{"value":"2168-6068","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10,1]]}}}